Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896463158> ?p ?o ?g. }
- W2896463158 abstract "Is oral dydrogesterone 30 mg daily non-inferior to 8% micronized vaginal progesterone (MVP) gel 90 mg daily for luteal phase support in IVF?Oral dydrogesterone demonstrated non-inferiority to MVP gel for the presence of fetal heartbeats at 12 weeks of gestation (non-inferiority margin 10%).The standard of care for luteal phase support in IVF is the use of MVP; however, it is associated with vaginal irritation, discharge and poor patient compliance. Oral dydrogesterone may replace MVP as the standard of care if it is found to be efficacious with an acceptable safety profile.Lotus II was a randomized, open-label, multicenter, Phase III, non-inferiority study conducted at 37 IVF centers in 10 countries worldwide, from August 2015 until May 2017. In total, 1034 premenopausal women (>18 to <42 years of age) undergoing IVF were randomized 1:1 (stratified by country and age group), using an Interactive Web Response System, to receive oral dydrogesterone 30 mg or 8% MVP gel 90 mg daily.Subjects received either oral dydrogesterone (n = 520) or MVP gel (n = 514) on the day of oocyte retrieval, and luteal phase support continued until 12 weeks of gestation. The primary outcome measure was the presence of fetal heartbeats at 12 weeks of gestation, as determined by transvaginal ultrasound.Non-inferiority of oral dydrogesterone was demonstrated, with pregnancy rates in the full analysis sample (FAS) at 12 weeks of gestation of 38.7% (191/494) and 35.0% (171/489) in the oral dydrogesterone and MVP gel groups, respectively (adjusted difference, 3.7%; 95% CI: -2.3 to 9.7). Live birth rates in the FAS of 34.4% (170/494) and 32.5% (159/489) were obtained for the oral dydrogesterone and MVP gel groups, respectively (adjusted difference 1.9%; 95% CI: -4.0 to 7.8). Oral dydrogesterone was well tolerated and had a similar safety profile to MVP gel.The analysis of the results was powered to consider the ongoing pregnancy rate, but a primary objective of greater clinical interest may have been the live birth rate. This study was open-label as it was not technically feasible to make a placebo applicator for MVP gel, which may have increased the risk of bias for the subjective endpoints reported in this study. While the use of oral dydrogesterone in fresh-cycle IVF was investigated in this study, further research is needed to investigate its efficacy in programmed frozen-thawed cycles where corpora lutea do not exist.This study demonstrates that oral dydrogesterone is a viable alternative to MVP gel, due to its comparable efficacy and tolerability profiles. Owing to its patient-friendly oral administration route, dydrogesterone may replace MVP as the standard of care for luteal phase support in fresh-cycle IVF.This study was sponsored and supported by Abbott. G.G. has received investigator fees from Abbott during the conduct of the study. Outside of this submitted work, G.G. has received non-financial support from MSD, Ferring, Merck-Serono, IBSA, Finox, TEVA, Glycotope and Gedeon Richter, as well as personal fees from MSD, Ferring, Merck-Serono, IBSA, Finox, TEVA, Glycotope, VitroLife, NMC Healthcare, ReprodWissen, Biosilu, Gedeon Richter and ZIVA. C.B. is the President of the Belgian Society of Reproductive Medicine (unpaid) and Section Editor of Reproductive BioMedicine Online. C.B. has received grants from Ferring Pharmaceuticals, participated in an MSD sponsored trial, and has received payment from Ferring, MSD, Biomérieux, Abbott and Merck for lectures. G.S. has no conflicts of interest to be declared. A.P. is the General Secretary of the Indian Society of Assisted Reproduction (2017-2018). B.D. is President of Pune Obstetric and Gynecological Society (2017-2018). D.-Z.Y. has no conflicts of interest to be declared. Z.-J.C. has no conflicts of interest to be declared. E.K. is an employee of Abbott Laboratories GmbH, Hannover, Germany and owns shares in Abbott. C.P.-F. is an employee of Abbott GmbH & Co. KG, Wiesbaden, Germany and owns shares in Abbott. H.T.'s institution has received grants from Merck, MSD, Goodlife, Cook, Roche, Origio, Besins, Ferring and Mithra (now Allergan); and H.T. has received consultancy fees from Finox-Gedeon Richter, Merck, Ferring, Abbott and ObsEva.NCT02491437 (clinicaltrials.gov).08 July 2015.17 August 2015." @default.
- W2896463158 created "2018-10-26" @default.
- W2896463158 creator A5002949801 @default.
- W2896463158 creator A5017357603 @default.
- W2896463158 creator A5023368779 @default.
- W2896463158 creator A5031366951 @default.
- W2896463158 creator A5032613678 @default.
- W2896463158 creator A5035447731 @default.
- W2896463158 creator A5045474888 @default.
- W2896463158 creator A5058801721 @default.
- W2896463158 creator A5061015930 @default.
- W2896463158 creator A5067986584 @default.
- W2896463158 date "2018-10-10" @default.
- W2896463158 modified "2023-10-14" @default.
- W2896463158 title "Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial" @default.
- W2896463158 cites W1795435863 @default.
- W2896463158 cites W1980755971 @default.
- W2896463158 cites W1986085565 @default.
- W2896463158 cites W2011657583 @default.
- W2896463158 cites W2013734819 @default.
- W2896463158 cites W2013843232 @default.
- W2896463158 cites W2014187827 @default.
- W2896463158 cites W2017938258 @default.
- W2896463158 cites W2027229987 @default.
- W2896463158 cites W2027963228 @default.
- W2896463158 cites W2034652444 @default.
- W2896463158 cites W2051108803 @default.
- W2896463158 cites W2065223935 @default.
- W2896463158 cites W2104233130 @default.
- W2896463158 cites W2108479208 @default.
- W2896463158 cites W2108947604 @default.
- W2896463158 cites W2126503856 @default.
- W2896463158 cites W2128146803 @default.
- W2896463158 cites W2134649289 @default.
- W2896463158 cites W2138440840 @default.
- W2896463158 cites W2165754964 @default.
- W2896463158 cites W2167191293 @default.
- W2896463158 cites W2168624327 @default.
- W2896463158 cites W2174524451 @default.
- W2896463158 cites W2244498840 @default.
- W2896463158 cites W2289016285 @default.
- W2896463158 cites W243077253 @default.
- W2896463158 cites W2473943285 @default.
- W2896463158 cites W2536490475 @default.
- W2896463158 cites W2546919281 @default.
- W2896463158 cites W2592864957 @default.
- W2896463158 cites W4210986798 @default.
- W2896463158 cites W4249987686 @default.
- W2896463158 cites W4294915367 @default.
- W2896463158 cites W48064796 @default.
- W2896463158 doi "https://doi.org/10.1093/humrep/dey306" @default.
- W2896463158 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6238366" @default.
- W2896463158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30304457" @default.
- W2896463158 hasPublicationYear "2018" @default.
- W2896463158 type Work @default.
- W2896463158 sameAs 2896463158 @default.
- W2896463158 citedByCount "39" @default.
- W2896463158 countsByYear W28964631582019 @default.
- W2896463158 countsByYear W28964631582020 @default.
- W2896463158 countsByYear W28964631582021 @default.
- W2896463158 countsByYear W28964631582022 @default.
- W2896463158 countsByYear W28964631582023 @default.
- W2896463158 crossrefType "journal-article" @default.
- W2896463158 hasAuthorship W2896463158A5002949801 @default.
- W2896463158 hasAuthorship W2896463158A5017357603 @default.
- W2896463158 hasAuthorship W2896463158A5023368779 @default.
- W2896463158 hasAuthorship W2896463158A5031366951 @default.
- W2896463158 hasAuthorship W2896463158A5032613678 @default.
- W2896463158 hasAuthorship W2896463158A5035447731 @default.
- W2896463158 hasAuthorship W2896463158A5045474888 @default.
- W2896463158 hasAuthorship W2896463158A5058801721 @default.
- W2896463158 hasAuthorship W2896463158A5061015930 @default.
- W2896463158 hasAuthorship W2896463158A5067986584 @default.
- W2896463158 hasBestOaLocation W28964631581 @default.
- W2896463158 hasConcept C126322002 @default.
- W2896463158 hasConcept C131872663 @default.
- W2896463158 hasConcept C143228043 @default.
- W2896463158 hasConcept C168563851 @default.
- W2896463158 hasConcept C187785154 @default.
- W2896463158 hasConcept C2776045411 @default.
- W2896463158 hasConcept C2777164284 @default.
- W2896463158 hasConcept C2779234561 @default.
- W2896463158 hasConcept C29456083 @default.
- W2896463158 hasConcept C46973012 @default.
- W2896463158 hasConcept C54355233 @default.
- W2896463158 hasConcept C71924100 @default.
- W2896463158 hasConcept C86803240 @default.
- W2896463158 hasConceptScore W2896463158C126322002 @default.
- W2896463158 hasConceptScore W2896463158C131872663 @default.
- W2896463158 hasConceptScore W2896463158C143228043 @default.
- W2896463158 hasConceptScore W2896463158C168563851 @default.
- W2896463158 hasConceptScore W2896463158C187785154 @default.
- W2896463158 hasConceptScore W2896463158C2776045411 @default.
- W2896463158 hasConceptScore W2896463158C2777164284 @default.
- W2896463158 hasConceptScore W2896463158C2779234561 @default.
- W2896463158 hasConceptScore W2896463158C29456083 @default.
- W2896463158 hasConceptScore W2896463158C46973012 @default.
- W2896463158 hasConceptScore W2896463158C54355233 @default.
- W2896463158 hasConceptScore W2896463158C71924100 @default.
- W2896463158 hasConceptScore W2896463158C86803240 @default.